Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
momenor 50 mikrogram/dosis næsespray, suspension
nordic prime aps - mometasonfuroat monohydrat - næsespray, suspension - 50 mikrogram/dosis
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
mometasonfuroat "paranova" 50 mikrogram/dosis næsespray, suspension
paranova danmark a/s - mometasonfuroat monohydrat - næsespray, suspension - 50 mikrogram/dosis
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
momenex 50 mikrogram/dosis næsespray, suspension
2care4 generics aps - mometasonfuroat monohydrat - næsespray, suspension - 50 mikrogram/dosis
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
mometasonfuroat "orifarm" 50 mikrogram/dosis næsespray, suspension
orifarm a/s - mometasonfuroat monohydrat - næsespray, suspension - 50 mikrogram/dosis
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
ledercort "rx" 50 mikrogram/dosis næsespray, suspension
dymalife pharmaceutical srl - mometasonfuroat monohydrat - næsespray, suspension - 50 mikrogram/dosis
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
metacort 50 mikrogram/dosis næsespray, suspension
s.f. group s.r.l. - mometasonfuroat monohydrat - næsespray, suspension - 50 mikrogram/dosis
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
mometasonfuroat "nordic prime" 50 mikrogram/dosis næsespray, suspension
nordic prime aps - mometasonfuroat monohydrat - næsespray, suspension - 50 mikrogram/dosis
Den Europæiske Union -
dansk -
EMA (European Medicines Agency)
enerzair breezhaler
novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - medicin for obstruktiv sygdomme, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.
Den Europæiske Union -
dansk -
EMA (European Medicines Agency)
bemrist breezhaler
novartis europharm limited - indacaterol, mometasone furoate - astma - medicin for obstruktiv sygdomme, - bemrist breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.
Den Europæiske Union -
dansk -
EMA (European Medicines Agency)
atectura breezhaler
novartis europharm limited - indacaterol acetate, mometasone furoate - astma - medicin for obstruktiv sygdomme, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.